1.LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115. PH, YTT: these authors contribute equally. Phillip_hsieh@dfci.harvard.edu, email@example.com, firstname.lastname@example.org; email@example.com
Waldenstroms Macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma (LPL), is lymphoproliferative disorder classified by the WHO as an indolent lymphoma. WM cells display characteristics of both lymphocytes and plasma cells with gene expression profiling revealing a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma (MM). At its core, WM is a clonal disease of B-lymphocytes and is characterized by the presence of (1) a monoclonal IgM immunoglobulin (M-protein), (2) malignant lymphoplasmacytic cell infiltration in the bone marrow. WM patients can present with symptoms/signs consistent with hyperviscosity syndrome when the M protein is conspicuous. Clinically, WM presents similarly to MM except that organomegaly and lymphadenopathies are common in WM but not in MM, and lytic bone disease and renal disease are uncommon in WM but common in MM.
Phillip Hsieh ; Yu-Tzu Tai ; Matthew Ho Zhi Guang ; Giada Bianchi
Atlas Genet Cytogenet Oncol Haematol. 2017-11-01
Online version: http://atlasgeneticsoncology.org/haematological/2043/waldenstrom-macroglobulinemia